Literature DB >> 2852652

Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH.

R T Dorr1, B V Dawson, F al-Obeidi, M E Hadley, N Levine, V J Hruby.   

Abstract

A toxicology study was performed in mice given a superpotent alpha melanocyte stimulating hormone (MSH) analog. This 13 amino acid derivative, [Nle4, D-Phe7]alpha-MSH or NDP-MSH, is a melanotropin which is very slowly biodegraded in vivo and is active at 1/1,000 the concentration of natural alpha-MSH. Mice were administered up to 2 mg/kg of the analog daily and weekly over 4 or 12 weeks by both topical application (in 90% DMSO) or by IP injections (in physiologic saline). At the end of this period, no toxic effects were observed in various organs, on hematologic indices, or on weight gain. A slight increase in triglyceride and platelet levels were noted in mice given the analog weekly for 12 weeks. There was no evidence of an effect on behavior nor ACTH-like endocrine actions such as elevated serum cortisol levels. Transdermal drug delivery studies performed in vitro showed reproducible diffusion of the NDP-MSH analog through full-thickness mouse skin. Approximately 0.002% to 0.05% of a 10(-4) M preparation was transdermally delivered using a DMSO/water solution or a PEG/alcohol cream base, respectively. This superpotent analog is now entering a Phase I clinical trial with possible therapeutic applications for the treatment of hypomelanotic disorders such as vitiligo and for pharmacologic tanning without the need for sunlight exposure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852652     DOI: 10.1007/bf00173642

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  17 in total

1.  The dual effect of melanocyte-stimulating hormone (MSH) on the growth of cultured mouse melanoma cells.

Authors:  R Halaban; A B Lerner
Journal:  Exp Cell Res       Date:  1977-08       Impact factor: 3.905

2.  Long-term and residual melanotropin-stimulated tyrosinase activity in S91 melanoma cells is density dependent.

Authors:  Z A Abdel Malek; K L Kreutzfeld; M E Hadley; M D Bregman; V J Hruby; F L Meyskens
Journal:  In Vitro Cell Dev Biol       Date:  1986-02

Review 3.  Topical corticosteroids.

Authors:  H I Maibach; R B Stoughton
Journal:  Med Clin North Am       Date:  1973-09       Impact factor: 5.456

4.  On the etiology of vitiligo and gray hair.

Authors:  A B Lerner
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

5.  Actions of melanotropins on mouse melanoma cell growth in vitro.

Authors:  Z A Abdel Malek; M E Hadley; M D Bregman; F L Meyskens; V J Hruby
Journal:  J Natl Cancer Inst       Date:  1986-05       Impact factor: 13.506

6.  Calcium-dependent prolonged effects on melanophores of [4-norleucine, 7-D-phenylalanine]-alpha-melanotropin.

Authors:  M E Hadley; B Anderson; C B Heward; T K Sawyer; V J Hruby
Journal:  Science       Date:  1981-08-28       Impact factor: 47.728

7.  Antipyretic activity of a potent alpha-MSH analog.

Authors:  M Holdeman; J M Lipton
Journal:  Peptides       Date:  1985 Mar-Apr       Impact factor: 3.750

8.  [Nle4, D-Phe7]-alpha-MSH: a superpotent melanotropin with prolonged action on vertebrate chromatophores.

Authors:  M E Hadley; J H Mieyr; B E Martin; A M Castrucci; V J Hruby; T K Sawyer; E A Powers; K R Rao
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1985

9.  Topical application of a melanotropic peptide induces systemic follicular melanogenesis.

Authors:  M E Hadley; S H Wood; A M Lemus-Wilson; B V Dawson; N Levine; R T Dorr; V J Hruby
Journal:  Life Sci       Date:  1987-05-11       Impact factor: 5.037

10.  4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.

Authors:  T K Sawyer; P J Sanfilippo; V J Hruby; M H Engel; C B Heward; J B Burnett; M E Hadley
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

View more
  4 in total

Review 1.  Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Authors:  Elisabeth I Minder; Jasmin Barman-Aksoezen; Xiaoye Schneider-Yin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 2.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

3.  Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole.

Authors:  Meera E Modi; Kiyoshi Inoue; Catherine E Barrett; Kara A Kittelberger; Daniel G Smith; Rainer Landgraf; Larry J Young
Journal:  Neuropsychopharmacology       Date:  2015-02-05       Impact factor: 7.853

4.  Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model.

Authors:  D A C Botte; I L Noronha; D M A C Malheiros; T V Peixoto; S B V de Mello
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.